AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain at EFIC 2023 Conference

STOCKHOLM, SE / ACCESSWIRE / September 20, 2023 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central …